Chapter 9
Phospholipase C

Colin A. Bill and Charlotte M. Vines

Abstract Phospholipase C (PLC) family members constitute a family of diverse enzymes. Thirteen different family members have been cloned. These family members have unique structures that mediate various functions. Although PLC family members all appear to signal through the bi-products of cleaving phospholipids, it is clear that each family member, and at times each isoform, contributes to unique cellular functions. This chapter provides a review of the current literature on PLC. In addition, references have been provided for more in-depth information regarding areas that are not discussed including tyrosine kinase activation of PLC. Understanding the roles of the individual PLC enzymes, and their distinct cellular functions, will lead to a better understanding of the physiological roles of these enzymes in the development of diseases and the maintenance of homeostasis.

Keywords Phospholipase C family · G protein-coupled receptors · Phosphatidylinositol 4 · 5 – bisphosphate · Diacylglycerol · Inositol 1 · 4 · 5 – triphosphate · Calcium · Isoform · Structure · Ubiquitous expression · Multiple functions

9.1 Discovery

In 1953, it was reported that the addition of acetylcholine or carbamylcholine to pancreatic cells led to the production of phospholipids [1]. In these studies, ^{32}P was used to detect a sevenfold increase in the levels of phospholipids in the samples treated with the drugs, when compared with control slices, which had remained un-stimulated. Although unrecognized at that time, this was the first evidence of

C. A. Bill · C. M. Vines (✉)
Department of Biological Sciences, Border Biomedical Research Center, The University of Texas at El Paso, El Paso, TX, USA
e-mail: cvines@utep.edu

© Springer Nature Switzerland AG 2020

M. S. Islam (ed.), *Calcium Signaling*, Advances in Experimental Medicine and Biology 1131, https://doi.org/10.1007/978-3-030-12457-1_9

the presence of phospholipase C (PLC) function in cells. More than 20 years later, in 1975, it was shown that impure preparations of PLC could be used to cleave phosphatidylinositol [2]. In 1981, the first purified preparation of PLC was isolated [3]. A couple of years later it was found that the inositol 1,4,5 trisphosphate (IP_3) generated from the cleavage of phosphatidyl inositol 4,5 bisphosphate (also known as PI (4,5)P_2 or PIP_2) could induce the release of Ca^{2+} from intracellular stores [4] (Figs. 9.1 and 9.2). This important observation provided new insight into the function of PLC in living organisms. Eventually, the PLCβ, PLCγ, PLCδ, PLCε, PLCη and PLCζ cDNAs were cloned [5–10]. Although PIP_2 is a minor phospholipid in the plasma membrane, it plays a central role in regulating a host of cellular processes. PLC is activated following stimulation of cells by either tyrosine kinase receptors, T-cell receptors, B-cell receptors, Fc receptors, integrin adhesion proteins or G protein-coupled receptors via cognate ligands including neurotransmitters, histamine, hormones and growth factors [11–15]. Signaling through PLC family members regulates diverse functions, which will be outlined within this chapter. In addition, we will discuss PLC mediated signaling, common structural domains found in this family of enzymes, current knowledge about the isoforms and areas that have yet to be explored.



Fig. 9.1 Different effectors activate signaling through PLC to induce cleavage of PIP_2 to yield diacylglycerol and inositol triphosphate



Fig. 9.2 PLC family members cleave PIP_2 to produce diacylglycerol and inositol triphosphate

9.2 Cleavage of PIP_2 and Signaling

PLC is a cytoplasmic protein that controls the levels of PIP_2 in cells by localizing within or outside of lipid rafts in the plasma membrane and catalyzing the hydrolysis of phosphorylated forms of phosphatidyl inositol in response to cellular stimuli (Figs. 9.1 and 9.2). These enzymes have been reported to increase the rate of lysis of phosphatidyl inositol >1000 s^{-1} at 30 °C at low concentrations of substrate, but is likely to reach rates of >5000 s^{-1} (as reviewed by [16]). Therefore, targeting of PLC to the plasma membrane plays a critical role in the functioning of this enzyme. The preferred substrate of PLC is PIP_2, a relatively uncommon phospholipid in the plasma membrane, followed by phosphatidyl inositol phosphate (PIP), and then phosphatidyl inositol (PI). Cleavage of PIP_2 leads to the generation of two products. One product, diacylglycerol (DAG), activates the calcium dependent protein kinase C (PKC), which then phosphorylates downstream effectors such as AKT to activate an array of cellular functions including regulating cell proliferation, cell polarity, learning, memory and spatial distribution of signals [17, 18]. DAG, which remains membrane bound, can then be cleaved to produce another signaling molecule, arachidonic acid. The second product of PLC action on PIP_2, IP_3 is a small water-soluble molecule, which diffuses away from the membrane, and through the cytosol to bind to IP_3 receptors on the endoplasmic reticulum inducing the release of Ca^{2+} from intracellular stores found within the organelle [4]. In turn, the cytoplasmic calcium levels are quickly elevated and cause the characteristic calcium spike that signals cell activation. Once the endoplasmic reticulum stores have been used up, they are replenished through the store-operated calcium channels. Ca^{2+} activates downstream transcription factors resulting in a plethora of gene activation pathways. In this way, signaling through PLC regulates proliferation, differentiation, fertilization, cell division, growth, sensory transduction, modification of gene expression, degranulation, secretion and motility [15, 19–26].

9.3 Structure of PLC

There are thirteen different PLC family members that can be subdivided into six classes, β, γ, δ, ε, η and ζ (Fig. 9.3). Different isoforms have been discovered in a wide range of species including mouse, rat and cattle. PLC-like isozymes have been found in *Drosophila melanogaster*, *Glycine max* (soybean), *Arabidopsis thaliana*, *Saccharomyces cerevisiae* and *Schizosaccharomyces pombe* [27, 28]. Overall, there is a low level of amino acid conservation between the family members; however, the similarity of the pleckstrin homology domains, the EF hand motifs, the X and Y domains and the C2 domains is greater than 40–50% [15]. Since these domains are common to all organisms they might represent a minimum requirement for a functioning PLC [29]. With the exception of the PH domain, which is not expressed on PLCζ, each family member shares all of the core domains. A description of each domain follows:



Fig. 9.3 Unique domains found in individual family members include the following: Post Synaptic density (PSD-95), Drosophila disc large tumor suppressor (DLgA) and Zonula Occludens-1 (ZO-1) (PDZ), src homology 2 (SH2)

9.3.1 Pleckstrin Homology (PH) Domains

As mentioned, with the exception of PLCζ, all PLC family members have N-terminal pleckstrin homology (PH) domains which consists of approximately 120 amino acids, and is the eleventh most common domain in the human genome. PH domains are found in a large number of distinct protein families involved in signal transduction [30]. PH domains can mediate recruitment of the PLC family members to the plasma membrane via phosphoinositides. Computer simulations and crystal structures of the PH domain found in kindlins, proteins which co-activate integrin adhesion proteins, have revealed that PH domains consist of 7 beta sheets and an alpha helix, and that the beta sheets form the PIP_2 binding site [31]. Surface plasmon resonance studies have revealed a 1mM affinity for PIP_2 within lipid bilayers.

Notably, membrane binding of PLCδ to PIP_2 is blocked by high levels of intracellular Ca^{2+} in hepatocytes due to generation of phosphoinositides [32]. This may also be due to the ability of Ca^{2+} to regulate the conformation of the headgroup of PIP_2 [33]. Unlike the PH domain of PLCδ1, which uses the PH domain to bind to the PIP_2 in the membrane, the PH domain of PLCβ2, cannot bind to phosphoinositides [34].

PLCγ contains 2 PH domains, one in the N-terminus and a C-terminal split PH domain. This PH domain of PLCγ is unique, since it is split between two tandem Src homology domains [35]. Early on, it was found that the carboxy-terminal region of the PH domains of PLCγ, PLCβ2 and PLCβ3 control the binding of heterotrimeric G protein βγ subunits to PLC following activation of G protein-coupled receptors [36, 37]. Interestingly, the binding of $G_{\beta\gamma}$ to the PH domain, and the binding of $G_{\beta\gamma}$ to Gα are mutually exclusive [36]. Therefore, this competition for binding to $G_{\beta\gamma}$ implicates PLC activation in preventing the regeneration of the $G\alpha/G_{\beta\gamma}$ heterotrimeric G proteins. In this way [34], PLC activation may regulate the signaling of proteins that are turned on in response to stimulation of G protein-coupled receptors. Additionally, downstream of SDF1α (CXCL12) binding to the G protein-coupled receptor CXC chemokine receptor 4 (CXCR4), the PH domains of PLCε1 promote lipase independent activation of Rap1, which leads to β2-integrin-mediated recruitment and adhesion of T-cells to sites of inflammation [38]. Overall, from these observations it can be inferred that PH domains have multiple roles in regulating the signaling via PLC.

In contrast to PLC signaling through heterotrimeric G-protein, it should be noted that Rap1 which belongs to the Rap-family of small GTPases and Ras-family small GTPases are also involved in PLC signaling. Rap and Ras are small, closely related GTP binding proteins. While Rap is an important factor in cell junctions and cell adhesion, Ras is linked to cell proliferation and survival [39]. Both of these small, monomeric G proteins also play critical roles in signaling through PLC as will be discussed below:

9.3.1.1 EF-Hand Motifs

The EF-hand motifs are helix-loop-helix motifs present in a number of calcium-binding proteins, such as myosin, calmodulin, calreticulin and troponin [40]. EF-hand motifs were first described for PLC when the crystal structure analysis of PLCδ1 revealed the characteristic helix-loop-helix motifs [41]. Within PLC, the EF-hand is part of the catalytic core that consists of an EF-hand, the X and Y and the C2 domains ([41] and see below). Upon binding to Ca^{2+}, the structure of PLC is stabilized as the EF-hand motifs undergo a conformational change to activate calcium-regulated functions, by exposing sites that become ligands for other proteins [42]. For example, in PLCβ, the EF-hands contain sites that mediate association with subunits of heterotrimeric G proteins, while in PLCγ, the EF-hands contain regions that lead to binding of tyrosine kinases [43]. Independent of the Ca^{2+} concentration, deletion of the EF-hands in the enzyme reduces PLC function, [44]; however, binding of Ca^{2+} to the EF-hand motifs can promote binding of PLC to PIP_2 via the PH domain. Lacking a PH domain, PLCζ may bind to membrane PIP_2 via cationic residues in the EF-hand [45] as well as the X-Y linker (as reviewed [46]).

9.3.1.2 X and Y Domains

So far, only PLCδ1 and PLCβ2 have been crystallized and their structures analyzed [34, 41]. The X and Y domains consist of approximately 300 amino acids and lie at the C-terminus of the EF-hand motifs. These domains consist of alternating α-helices and β-sheets that form aβaβaβaβ motif with a triosephosphate isomerase (TIM) barrel-like structure [41]. The X-region, containing all of the catalytic residues, is somewhat conserved across the PLC family members [27, 41]. The X-region forms one half of the TIM-barrel like structure. Within the X-region lies histidine residues that support the generation of the 1,2 cyclic inositol 4,5-bisphosphate [47]. The catalytic activity of this domain increases as the concentration of Ca^{2+} rises from 0.01μM to 10μM. Mutational analysis of rat PLCδ1 revealed that $histidine^{311}$ and $histidine^{356}$, which are crucial for catalyzing the hydrolysis of PIP_2, have an important role within the X domain [47]. These residues are well conserved in PLC family members [47].

Structurally, the Y-domain (residues 489–606) forms the other half of the TIM-barrel-like architecture. This eightfold barrel structure is almost always found within an enzyme that regulates metabolism [48], although the functions of the enzymes are quite diverse. With the exception of an extended loop connection between the β5 and β6 strand, instead of a helix, this domain forms the second half of the TIM-barrel-like structure. This Y-domain is important for substrate recognition and regulates the preference of PLC for PIP_2, PIP and PI [49, 50].

PLCγ contains a unique region that splits the X and Y domains. This region contains the split PH domains at the ends and the middle consists of two N-terminal src homology (SH2) domains followed by an SH3 domain. The SH2

domains provide docking sites for tyrosine kinase growth factor receptors such as the platelet derived growth factor receptors (PDGFRs) and the epidermal growth factor receptors (EGFRs) to promote activation of this PLC family member [51–53]. The binding of tyrosine kinase receptors to PLCγ results in phosphorylation and activation of the enzymes [54, 55]. The SH3 domain directs the cellular localization of signaling proteins such as dynamin and the actin cytoskeleton. In addition, the SH3 domains have been found to mediate nerve growth factor-induced cell proliferation through activation of a guanine nucleotide exchange factor for phosphoinositide 3 kinase (PI3K) [56, 57].

9.3.1.3 C2 Domains

C2 domains are formed from about 120 amino acids [58] and can be found in more than 40 different proteins [41]. These motifs have several binding targets and have been implicated in signal transduction and membrane interactions. The C2 domains found within PLC family members are formed by an eight-stranded anti-parallel β-sandwich [41]. There are between three and four C2 domains found within PLCδ family members. In combination with Ca^{2+}, the C2 domain mediates the binding of PLCδ1 to anionic phospholipids to mediate signal transduction and membrane trafficking [43]. C2 domains have common structural motifs, which are found in PKCβ, rabphilin 3A [59, 60], and synaptotagmin I [61]. High cooperativity of calcium-dependent phospholipid binding sites implies that there are multiple sites that bind Ca^{2+}, which function synergistically [43].

C2 domains belong to the non-continuous Ca^{2+}-binding sites in which the Ca^{2+}-binding pockets are found far from each other in the amino acid sequence. In contrast EF-hands have binding pockets for Ca^{2+}produced by a stretch of continuous amino acids in the primary sequence [62, 63]. Functionally, the EF-hand motif, the most common Ca^{2+} binding motif in proteins, may compete for binding to Ca^{2+} with the C2 domains. The affinity of the EF-hand for Ca^{2+} is within the nanomolar to millimolar range, which overlaps the micromolar to millimolar binding constants of C2 domains [64, 65]. This broad affinity of C2 domains for $[Ca^{2+}]$ reflects the diversity of the functions of proteins containing the C2 domains over a wide range of calcium concentrations [66–68].

9.3.1.4 PDZ Domains

PDZ (Post synaptic density (PSD)-95, Drosophila disc large tumor suppressor (DlgA), and Zonula occludens-1 protein (zo-1)) regions are separate from C2 domains, and are found in the C-terminal tails of PLCβ and PLCη lipases (Fig. 9.1) [58]. The PDZ domains are formed by 5 of 6 β-strands and 2 or 3 α-helices [69]. This common structural motif is found in many signaling proteins, where it functions as a scaffold for large molecular complexes [70]. In this way, the motif links many proteins to signaling from the cytoskeletal membranes. It has been postulated that

each PLCβ form may be used by different G protein-coupled receptors in regulating signaling events [71]. The sequences within the last five amino acids of the C-terminus are thought to regulate the specificity of the interaction of PLC with the Gα or Gβγ subunits [72].

9.4 Roles of Each PLC

As mentioned, there are six PLC family members (β, γ, δ, ε, η and ζ) consisting of thirteen different PLCs identified based on structure (Fig. 9.3) and activation mechanism. There is no alpha form of PLC, since the protein that was originally described as the α form turned out to be a protein disulfide isomerase without phospholipase activity [73]. Under most conditions, PLC is a cytoplasmic protein that moves to the plasma membrane. Its role within the membrane lipid rafts is somewhat controversial. For instance, PLC has been shown to accumulate within lipid rafts that consist of cholesterol, sphingomyelin and ceramide, *Xenopus* egg activation, catalyzing the hydrolysis of PIP_2 within these frog eggs [16, 74]. In contrast, PLC associates with the tyrosine kinase HER2 within non-raft domains in ovarian cancer cells [72]. In eggs and in ovarian cancer cells, PLC catalyzes hydrolysis of PIP_2 to promote classic functions (Fig. 9.2 and 9.3). With the exception of PLCγ2, there have been splice variants reported for each PLC isoform (as reviewed by [28, 44]). For PLC a different gene encodes each isoform. The diversity of the PLC isoforms is created with splice variants. PLC isoforms are quite distinct in regard to tissue distribution, cell localization, expression and regulation. PLCβ and PLCγ are typically activated by extracellular stimuli and are termed first line PLC's, whereas PLCδ, ε, η and ζ are activated by intracellular stimuli and known as secondary PLC's [75]. For the purposes of this chapter, we will focus on the general properties described for each isoform.

9.4.1 *PLCβ*$_{1,2,3,4}$

There are four isoforms of PLCβ that range in size from 130 kDa for PLCβ4, 140 kDa for PLCβ2, 150 kDa for PLCβ1 and 152 kDa for PLCβ3. In addition, splice variants have been reported for each of these isoforms [76–78]. The PLCβ subfamily consists of a well-conserved core structure with an N-terminal PH domain, four EF-hands, a split X + Y catalytic domain, C2 domain and an extended C-terminal domain (Fig. 9.3). The catalytic domain being the most conserved domain of all PLC's isozymes with a substrate preference for PIP2 over PIP and PI [79]. PLCβ family members show distinct tissue expression and G protein regulation. PLCβ1 and PLCβ3 are ubiquitously expressed, whereas PLCβ2 and PLCβ4 are found only in hematopoietic and neuronal tissues, respectively [80]. These well-characterized isoforms of PLC are classically activated by G protein-coupled receptors and their

catalytic activity is entirely dependent upon Ca^{2+}. All four PLCβ isoforms are activated by $G\alpha_q$ subunit. PLCβ2 and PLCβ3 can also be activated by βγ subunits of the $G\alpha_{i/o}$ family of G proteins and by small GTPases such as Rac and Cdc42 (Figs. 9.1 and 9.3). In addition, PLCβ's are GTPase-activating proteins (GAPs) for the $G\alpha_q$ proteins that activate them [80, 81]. While $G\alpha_q$, $G\alpha_{11}$, and $G\alpha_{16}$ can activate PLCβ1, PCLβ2 and PLCβ3 family members [82]. In this case, the G protein-coupled receptor is stimulated by binding to its ligand, undergoing a conformational change to release $G\alpha_q$ or $G\alpha_{i/o}$ and Gβ/γ [81, 83, 84]. PLCβ is recruited to the membranes through interactions with Gβγ, but not Gαq [85]. In addition, PLCβ is recruited only through specific Gα subunits and the Gβγ subunits. These studies demonstrate that the PLC family members respond not only to Gα, but to Gβγ as well [37, 86]. Phosphoinositide-specific-phospholipase C β (PLCβ) is the main effector of $G\alpha_q$ stimulation that is coupled to receptors binding acetylcholine, dopamine, bradykinin, angiotensin II, other hormones and neurotransmitters [87].

The PLCβ family members have an additional 450 amino acid residues in the C-terminus (Fig. 9.3). While all PLCβ family members have been found in the nucleus, PLCβ1 is the major nuclear PLC [88–90]. Within this C-terminal 450 amino acid region, lies the greatest dissimilarity between PLC family members. In this region of the PLCβ1a and 1b splice variants is a nuclear localization signal, which directs localization of PLCβ1 isoforms, mostly to the nucleus while a nuclear export signal allows PLCβ1a to remain in the cytosol [77]. The likely consequence of DAG generation inside the nucleus is activation of nuclear PKC [91, 92]. Nuclear PLCβ1 regulates the cell cycle by modulating cyclin levels with cells overexpressing PLCβ1 producing increased levels of Cyclin D3 and a higher percentage of cells in S phase, in an erythroleukemia cell line [92, 93]. The binding site for Gαq is found within a region that mediates activation of Gαq by regulator of G protein signaling 4 (RGS4) and G alpha interacting protein (GAIP), which are GTPase-activating proteins (GAPs) [94]. This binding site blocks activation of PLCβ [95]. PLCβ1 is expressed at high levels in the cerebral cortex, retina, hippocampus and cardiomyocytes [96–98].

As mentioned, the expression of PLCβ2, which shares 48% identity with PLCβ1, appears to be restricted to cells of the hematopoietic lineages [99]. PLCβ2 can be activated by Rac, a member of the Rho-family of kinases [100]. The PH domain of PLCβ2 mediates binding of active forms of Rac (Rac1, Rac2 and Rac3), which leads to activation [101]. In contrast to PLCβ1 and PLCβ2, PLCβ3 lacks 10–20 amino acids within its C-terminus [102], although the significance of this difference is unknown. This PLC isoform is expressed by liver, brain and parotid gland [102].

PLCβ1 and PLCβ4 are expressed within the brain including the cerebral cortex, amygdala, hippocampus, and olfactory bulb and are thought to be involved in brain development and synaptic plasticity [91, 103–105]. Mis-regulation of PLCβ1 and/or PLCβ4 have been linked to several brain conditions such as schizophrenia, epilepsy, depression, Alzheimer's disease, bipolar disease and Huntington's disease [105–107]. In addition, studies of PLCβ1$^{-/-}$ mice revealed roles for PLCβ1 in regulating

vision and central nervous system homeostasis and loss of PLCβ1 can lead to seizures and sudden death [108].

PLCβ1 plays important roles in cell differentiation, particularly in osteogenesis, hematopoiesis and myogenesis [79, 80, 109]. At least for myogenic differentiation, PLCβ1 signaling involves inositol polyphosphate multikinase and β -catenin as downstream effectors. By means of c-jun binding to cyclin D3 promoter, the activation of PLC β 1 pathway determines cyclin D3 accumulation and muscle cell differentiation [110]. Also, PLCβ participates in the differentiation and activation of immune cells involved in both the innate and adaptive immune systems including, macrophages, neutrophils, mast cells, T cells and B cells [79]. Consistent with a role of PLCβ3 in neutrophil development, it was reported that PLCβ3$^{-/-}$ mice develop myeloproliferative neoplasm with increased mature neutrophils [80].

A role for PLCβ in several cancers has been proposed. Recently, it has been reported that PLCβ2 acts as a negative regulator of triple negative breast cancer since up-regulation in invasive triple negative breast cancer cells was sufficient to lower the expression of surface antigens required for malignancy and to reduce the number of cells with a stem-like phenotype suggesting that enhancing PLCβ2 expression is a potential therapy for triple negative breast cancer [111]. Similarly, a high expression of PLCβ1 was associated with an enhanced long-term survival of patients with a proneural subtype high grade gliomas [112] and patients affected by myelodysplastic syndromes showed a reduced propensity to develop acute myeloid leukemia when the expression of nuclear PLCβ1 was reduced [91].

9.4.2 PLCγ$_{1,2}$

There are two isoforms of PLCγ, PLCγ1 and PLCγ2. PLCγ1 is ubiquitously expressed, and operates downstream of tyrosine kinase growth factor receptors such as vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), PDGF and EGF, whereas PLCγ2 is primarily expressed in hematopoietic cell lineages, often functioning downstream of immune cell receptors (Fig. 9.1 and [113, 114]). PLCγ subtypes are primarily activated by receptor tyrosine kinases (RTKs). Both PLCγ1 [115] and PLCγ2 can be activated by adhesion receptors, such as integrins [116]. PLCγ1 signaling acts via direct interactions with other signaling molecules via SH domains, as well as its lipase activity [117]. Some PLCγ signaling via nonreceptor tyrosine kinases has been reported [118, 119], including the B-cell receptor and via the Spleen tyrosine kinase (Syk)-activated PLCγ2 signaling in T cells [120] or osteogenic differentiation of bone marrow stromal cells [121]. PLCγ has important roles in differentiation, proliferation, transformation, calcium flux and tumorigenesis [22, 25, 122, 123]. In addition, it has been shown that PLC γ1 is activated by Src tyrosine kinase in Xenopus [124].

PLCγ can regulate proliferation by functions that are independent of its lipase activity. One example is that DNA synthesis does not require phospholipase function, but instead is regulated through the SH3 recruitment of a Ras exchange

factor, SOS1 [125]. In addition to the PH domain found in the N-terminus, these PLCγ family members have a second PH domain, which is split into an N-terminal domain of the PH domain that flanks two SH2 domains, followed by an SH3 domain and a C-terminal PH domain (Fig. 9.3). This C-terminal is thought to bind directly to the TRPC3 calcium channel, which then leads to agonist-induced calcium entry into the cell [35]. In addition, Vav1, c-Cbl and Slp76, via interactions with either the SH3 domain or the C-terminal SH2 domain are also required to help stabilize the recruitment of PLCγ1to the plasma membrane [126]. PLCγ2 and PKC are important upstream signals of macrophage-colony stimulating factor (M-CSF) and granulocyte-colony stimulating factor (G-CSF) that regulate myelopoiesis through cytokine production. These pathways activate ERK1/2, NFAT and JAK1/STAT-3 pathways [127]. PLCγ isoforms have been reported to be expressed in several innate immune cell types, including natural killer cells, macrophages, neutrophils and mast cells [128–131]. PLCγ activates the innate immune system by regulating respiratory bursts, phagocytosis, cell adhesion, and cell migration. PLCγ also modulates the inflammatory response by controlling Toll-like receptor-mediated signaling [132]. T cells express more PLCγ1 than PLCγ2 and PLCγ1 is activated by ligation of the T cell antigen receptor [126] and recruitment of PLCγ1 by Linker of Activated T cells (LAT) to the plasma membrane [133]. Phosphorylated LAT, in turn, serves as the primary docking site for the amino terminal SH2 domain of PLCγ1 to the membrane [134, 135]. All three SH domains of PLCγ1, however, are required to stabilize association of PLCγ1 with LAT, which is required to activate T cells [126]. Following engagement of the TCR, PLCγ1 production of DAG leads to activation of not only PKC, but also Ras guanyl releasing protein (GRP)-dependent signaling events [136, 137].

PLCγ1 is also activated by certain G protein-coupled receptors. We have shown that PLCγ1 can be activated following stimulation by the G protein-coupled receptor, C–C chemokine Receptor 7, a $G\alpha_{i/o}$ receptor, to mediate activation of β1 integrin, heterodimeric adhesion receptors [138]. In addition, PLCγ1 and PLCγ2 are both activated by the angiotensin and bradykinin G protein coupled receptors.

Homozygous disruption of PLCγ1 in a mouse model revealed that this PLC plays an essential role in growth and development [139]. In the absence of PLCγ1, the mice die at day E9.0, although until that stage of development the embryos appear normal. This mouse model revealed that although other PLCγ family members might be available, the role of PLCγ1 is essential and is not compensated by another PLC. In contrast, homozygous deletion of PLCγ2 leads to defects in platelet functions that are stimulated through β1 and β3 integrin adhesion proteins [140, 141]. PLCγ2 plays an essential role in B cell development, and function [20, 26]. Similar to PLCβ2, Rac, a member of the Rho-family of GTPases, can bind to and activate PLCγ2 [100]. This PLC family member can be activated through interactions with growth factor receptors, via phosphorylated tyrosines within their cytoplasmic tails via their intracellular tyrosine activation motifs (ITAMs). PLCγ2 also regulates calcium oscillations induced by the transcription factor, Nuclear Factor of Activated T cells (NFAT). Additionally, the SH2 domains can mediate activation of this receptor.

A role for PLCγ in neural development and certain neurological condition has become increasingly evident. PLCγ1 is highly expressed in the brain and is required for normal neuronal development and activation [114]. Since deregulation of PLCγ1 activation in response to brain derived neuronal factor can alter calcium influx and actin rearrangements that control neuronal migration, this PLC has been linked to diverse neurological disorders, including epilepsy, Huntington's disease and depression [114]. In this case mis-regulation of PLCγ1 function has been observed in animal models of Huntington's disease [142]. Moreover, genomic analysis has revealed a PLCγ2 variant that appears to be protective against Alzheimer's disease, possibly acting via microglia-modulated immune responses [143]. Other physiological roles for PLCγ are provided by recent evidence suggesting that PLCγ1 activates Akt-mediated Notch1 signaling, which is required for intima formation of blood vessels, and also plays a role in influenza viral entry into human epithelial cells [144, 145].

PLCγ1 is often mutated and highly expressed in several cancers being involved in tumorigenic processes including migration, invasion and in some cases, proliferation (as reviewed by [146]). Moderately to poorly differentiated breast tumors showed significantly higher levels of PLCγ1, compared with well differentiated tumors [147, 148]. Also, three distinct mutations in PLCγ2 were described in patients with chronic lymphocytic leukemia that were resistant to Ibrutinib treatment [148]. Indeed, studies have shown that mutated DNA sequences associated with human cancers and autoimmune diseases are well conserved between PLCγ1 und PLCγ2 and these mutations are gain-of-function effectors that destabilize normal regulatory signaling [149].

9.4.3 PLCδ$_{1, 3, 4}$

There are three identified isoforms of PLCδ with similar amino acid sequences that are highly evolutionary conserved from lower to higher eukaryotes [150]. PLCδ family members are activated by levels of calcium that are normally found in the cytoplasm (10^{-7}M to 10^{-5}M), making them one of the most calcium sensitive PLC isoforms [151, 152]. While PLCδ1 is localized to the cytoplasm in quiescent cells, this PLC isoform shuttles between the nucleus and the cytoplasm in active cells [153]. Human PLCδ4 was found to be primarily nuclear in human adipose derived mesenchymal stem cells [154]. Depletion of PLCδ1 leads to a block in the cell cycle [155]. PLCδ family members are thought to have a role in potentiating calcium signaling [151]. This form of PLC is similar to non-mammalian forms of PLC [15, 156] PLCδ1 can be activated by $G_{i/o}$ and Ga_q following stimulation of G protein-coupled receptors [157]. PLCδ is involved in regulating the activation of the actin cytoskeleton. Studies using PLCδ knockout mice have shown that PLCδ1 is required for maintenance of skin homeostasis; a recent study suggested that PLCδ1 is required for epidermal barrier integrity [158], whereas PLCδ3 regulates microvilli genesis within the intestine and the directed migration of neurons in

the cerebral cortex of developing brains [159, 160]. Knockout of both PLCδ1 and PLCδ3 resulted in embryonic lethality [161].

Similar to PLCγ1, mis-regulation of PLCδ1 has been linked to Alzheimer's disease [162]. Interestingly, this enzyme function is inhibited by sphingomyelin, a membrane lipid that is found in high concentrations in neurons. PLCδ1 is also mis-regulated in rat models of hypertension [163]. In addition, a decrease in PLCδ1 downregulation in cystic fibrosis cells resulted in dysregulation of Transient Receptor Potential Vanilloid 6 channel activity leading to an increase in the constitutive calcium influx, exacerbating cystic fibrosis effects [164].

PLCδ1 is expressed at high levels in hair follicles. Homozygous deletion of PLCδ1 leads to hair loss [165, 166]. The hair loss was due to an increase in leukocytes, specifically macrophages, neutrophils and T cells within the hair follicle [166]. Homozygous deletion of *Plcδ3* or *Plcδ4* had no apparent affect and the mice appeared normal.

During fertilization, a transient increase in Ca^{2+} precedes egg activation. Like other forms of PLC, this isoform appears to play a role in fertilization. Notably, PLCδ4$^{-/-}$ male mice are sterile [167, 168]. Even when PLCδ4$^{-/-}$ sperm were injected into eggs, few viable embryos developed. These studies implicate this family member in the regulation of fertilization [167]. In the same study, sperm isolated from PLCδ4 knockout mice were found to be inferior to sperm isolated from wild type mice in that the Ca^{2+} oscillations in these mice were delayed or did not occur at all [167].

Similar to several other PLC's, PLCδ's role in carcinogenesis is controversial. In one study, high expression levels of PLCδ significantly correlated with a shorter disease-free survival of patients with poorly-differentiated breast tumors suggesting a possible role as a tumor promoter [147]. In contrast, an unrelated study found that downregulation of PLCδ1 in breast cancers induced cell migration and invasion in an in vitro assay by inhibiting the phosphorylation of ERK1/2, suggesting a role as a tumor suppressor [169]. In support of the tumor suppressor effects, another study in colorectal cancer revealed that expression of PLCδ1, as shown by immunohistochemistry, was down-regulated in colorectal cancer samples, which was also linked to suppression of ERK1/2 phosphorylation [170] and increased autophagy of the colorectal cancer cells [171]. These results are in line with the concept that PLCδ1 may function as a tumor promoter or as tumor suppressor [147], and it is clear that further studies are needed to clarify the role of PLCδ in carcinogenesis.

9.4.4 PLCε

PLCε is the largest of the PLC family members with an apparent molecular weight of ~230 kDa and was originally described in 1998 as a Let-60 Ras binding protein [172]. Two splice variants of PLCε have been reported, termed PLCε1a and PLCε1b that are widely expressed, but distinct roles for these variants have

not been described [173]. PLCε is expressed at the highest levels in the heart, liver and lung, but can also be found in the skeletal muscle, spleen brain, lungs, kidneys, pancreas, testis, uterus, thymus and intestine [7, 174, 175]. This class of PLC, which was originally identified in *Caenorhabditis elegans*, and was later cloned in humans [7, 172, 174, 175]. The Ras-associated (RA) domains consist of approximately 100 amino acids that interact directly with the Ras-family GTPases, Ras [7, 175] and Rho [176]. A point mutation at a lysine residue in the RA2 domain of PLCε is sufficient to prevent Ras binding of the enzyme in a GTP-dependent manner [7]. Subsequently, it was found that PLCε could also be activated by the Gα_{12} and Gβ/γ released by activated G protein-coupled receptors [175, 177]. Later, it was shown that hydrolysis of Golgi-associated phosphatidylinositol 4- phosphate (PI4P) in cardiac myocytes is mediated by Gβγ via the RA2 and N-terminal CDC25 and cysteine-rich domains [178, 179]. G protein-coupled receptors that activate PLCε include the adrenergic and PGE receptors. At the same time Gαs has been shown to stimulate activation of PLCε [180] while Gα_{12} and Gα_{13} can activate RhoA which can stimulate PLCε [180, 181]. Not only is this PLC family member activated by Ras and RhoA, it can also function as a guanine nucleotide exchange factor (GEF) for the Ras superfamily of GTPases [175]. In a contrasting study, the CDC25 domain of PLCε was found to serve as a GEF for Rap1 but not for other Ras family members [182]. These characteristics of PLCε reveal that this enzyme can be activated not only by subunits of heterotrimeric G proteins, but also by small GTPases.

This ability of PLCε to be regulated by both Ras and Rho suggest that it can contribute to both proliferation and to migration. More interestingly, since PLCβ can be activated by Rho, both PLC family members may work together to regulate signal transduction pathways that are activated following stimulation of cells by Rho to control cell migration. Similarly, since PLCε can be regulated by Ras, a downstream effector of PLCγ signaling following activation of growth factor receptors such as the EGF receptor, the signaling pathways may work together to promote proliferation. The ability of PLCε to coordinate signaling through these pathways points to regulatory mechanisms that may be more complex than originally thought.

Since PLCε can regulate inflammatory ligands for G protein-coupled receptors, it was suggested that PLCε may protect against ischemia/reperfusion injuries [183]. In contrast, in a separate study it was shown that PLCε is often upregulated in patients with heart failure [184] and recently it was shown that chronic activation of this isoform leads to cardiac hypertrophy [178]. Additionally, PLCε-null mice have abnormal development of aortic and pulmonary valves [185]. The role of PLCε in carcinogenesis is controversial, although the enzyme is thought to play important roles in the regulation of cancer development and progression, possibly acting as either an oncogene or tumor suppressor depending upon the type of tumor [186, 187]. Inflammatory processes induced by PLCε are thought to be involved in the progression towards cancer [188]. Mutation analysis of the PLCE1 gene landscape via The Cancer Genome Atlas (TCGA) database showed that PLCE1 is an often-

mutated gene in several types of cancer, in particular digestive tract cancer such as gastric cancer and esophageal squamous carcinoma, but also including skin cancer, lung cancer and head and neck cancers [187].

9.4.5 PLCη$_{1,2}$

PLCη consists of two members that are the most recently discovered PLC's and are most closely related to PLCδ subtype [189]. The sequence homology between PLCη$_1$ and PLCη$_2$ are ~50% similar. PLCη1 has an apparent molecular weight of 115 kDa in mouse and humans, while PLCη2 is larger at 125 kDa. PLCη can be activated by G protein-coupled receptors and RTK's [190] with PLC activity amplified by both intracellular Ca^{2+} mobilization and extracellular Ca^{2+} entry [191]. PLCη sequence analysis showed a novel EF-hand domain including a non-canonical EF-loop 2 sequence that is responsible for the enhanced binding of Ca^{2+} and enhanced hydrolysis of PIP_2 [189]. The PLCη$_1$ and PLCη$_{2,}$ isoforms are localized to the brain and neurons and are extremely sensitive to changes in calcium levels within the physiological range [8, 9, 192, 193]. Like PLCδ, this form of PLC responds to the 100 nM calcium concentrations found inside the cell [194]. However, PLCη is more sensitive than PLCδ [8] and PLCη can modulate a sustained Ca^{2+} release via production of IP_3 [189].

PLCη2 is expressed in the infant brain, specifically in the hippocampus, cerebral cortex and olfactory bulb [9], where it may play an important role in calcium mobilization required for axon growth and retraction, growth cone guidance, the generation of synapses and neurological responses [9]. In humans, loss of the human chromosomal region, which encodes PLCη2 has been linked to mental retardation [195] and role for PLCη2 in neurite growth has been postulated [196]. Alzheimer's disease has been linked to altered calcium homeostasis within neurons of the central nervous system with calcium accumulation occurring in disease affected neuronal cells [197]. Since PLCη is expressed in these same regions of the brain, a potential role for PLCη in Alzheimer's disease pathogenesis has been postulated [197].

9.4.6 PLCζ

PLCζ is the smallest of the mammalian PLC family members with a molecular mass of ~70 kDa in humans and ~74 kDa in mice [10, 198]. Interestingly, studies have shown PLC-like activities in plants with non-specific PLC hydrolyzing membrane phospholipids like phosphatidylcholine (PC) and phosphatidylethanolamine and another PLC with structural similarities to PLCζ [29]. In mammals, PLCζ expression has been confined to sperm heads [10, 198, 199] where it serves to activate eggs during fertilization [10, 200]. Subsequent studies have also identified further mammalian orthologues of PLCζ in human, hamster, monkey, and horse

sperm [201, 202]. Although some studies suggested the possibility that a post-acrosomal sheath WW domain-binding protein, termed PAWP, could be responsible for eliciting Ca^{2+} oscillations at egg activation [203–205], more recent studies now convincingly suggest that PAWP is not required to stimulate Ca^{2+} oscillations during egg activation, while strong evidence supports PLCζ as a soluble sperm factor responsible for the Ca^{2+} oscillations [206–210].

In line with its key role as a sperm factor, PLCζ generally localizes to distinct regions of the sperm head in mammals [211–213]. In humans, three distinct populations of PLCζ within the sperm head have been determined in the acrosomal, equatorial and post-acrosomal regions [211, 214–216]. Although this is the only isoform of PLC identified, which lacks the N-terminal PH domain, it shares the closest homology with PLCδ1 [217]. The absence of the PH domain demonstrates that presence is not required for membrane localization of PLCζ. It is unclear, however, how PLCζ targets the plasma membrane in the absence of the PH domain. There is some indication that the C2 domain may contribute to targeting PLCζ to membrane-bound PIP_2. Following fusion of sperm with the egg, PLCζ is released into an egg, which until that point, is arrested at the second meiotic division. Ca^{2+} oscillations that mediate activation of an egg are due to IP_3 mediated Ca^{2+} release. The presence of PLCζ within the cytoplasm leads to Ca^{2+} oscillations, which are classically observed during activation of the egg and release from the meiotic arrest [218]. In addition, immuno-depletion of PLCζ suppresses Ca^{2+} release. After the egg is fertilized the Ca^{2+} oscillations end when the pronuclei merge [219, 220]. Sperm from infertile men who are unable to activate eggs have been reported to exhibit reduced or abolished types of PLCζ [214, 216, 221]. Also, the proportion of sperm expressing PLCζ correlates with fertilization rates following intracytoplasmic sperm injection making PLCζ a diagnostic marker of fertilization [75].

9.5 Methods to Inhibit PLC

There are several chemical inhibitors that can be used to block PLC function. A commonly used pan inhibitor, 1-[6-((17β-3-methoxyestra-1,3,5(10)trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione, (U73122), of phospholipase C, is thought to function by blocking translocation of the enzyme to the membrane [222]. For example, using 2 μM U73122 in contrast to the control U73343, we found that stimulation of CCR7 through one of its ligands, CCL21 [138], but not CCL19 promoted PLC dependent migration of T cells via β1 integrin adhesion proteins. In the same study, we were able to determine that the PLCγ1 isoform regulated migration by preventing CCL21 directed migration with targeted siRNA. This data suggests that one G protein-coupled receptor can activate PLCγ1 through two different ligands to control migration in T cells. In this case we speculate that PLCγ1

mediates integrin activation through inside-out signaling leading to activation of β1-integrins.

Recently, it has been shown that U73122 forms covalent associations with human PLCβ3, when the phospholipase is associated with mixed micelles [223]. While U73122 has been used as a pan inhibitor of PLC in numerous studies [21, 138, 224–228], in the study by Klein et al., instead of inhibiting PLC, U73122 activated human PLCγ1, human PLCβ2 and human PLCβ3, which had been incorporated into micelles to differing magnitudes. Since the PLC used in these studies was in a purified form, it is unclear, how U73122 functions to regulate the extent of PLC activation. In a second study, 1 μM U73122 was found to directly inhibit G protein activated inwardly rectifying potassium channels. This was in contrast to a second PLC inhibitor, 2-Nitro-4-carboxyphenylN,N -diphenylcarbamate (NCDC), which did not have that effect [229]. NCDC, however, is also thought to have non-specific effects that are not related to PLC functions [230].

It should also be noted that in rabbit parietal cells, use of the U73122 led to a number of unexpected effects including mis-regulation of Ca^{2+} mobilization, and acid secretion induced by an agonist. Of equal concern, the negative control U73343 blocked acid secretion [231]. Therefore, this PLC inhibitor when used, should be used with caution.

Similarly, there are at least three other known inhibitors and two activators of PLC, yet they are not specific. These inhibitors include O-(Octahydro-4,7-mthano-1H-iden-5-yl)carbonopotassium dithioate, [232], Edelfosine [233] and RHC 80267 (O,O′[1,6-Hexanediyl*bis*(iminocarbonyl)]dioxime cyclohexanone) [234]. The two activators are *m*-3M3FBS (2,4,6-Trimethyl-*N*-[3-(trifluoromethyl)phenyl]benzenesulfonamide), and the ortho version *o*-3M3FBS [235].

Heterozygous deletion of a specific PLC family member via siRNA, however, can yield targeted results [138]. As mentioned, in these studies, PLCγ1 specific siRNA was used to confirm the role of this PLC isoform in the regulation of β1 integrins during the adhesion of primary T cells. In the future it may be advisable to determine the specific PLC family member involved in a cellular response, by using siRNAs. More recently the discovery of Clustered Regularly Spaced Short Palindromic Repeats-Cas9 (CRISPR Cas9) technology, which was originally described in bacterial systems, allows for long-term targeted disruption or in some cases activation of specific genes [236, 237]. This technology, will likely be used to target specific PLC isoforms in the future.

The highly specific 3-phosphoinositide-dependent protein kinase 1(PDK1) inhibitor 2-O-benzyl-myo-inositol 1,3,4,5,6-pentakisphosphate (2-O-Bn-InsP5) can also block PLCγ1 dependent cell functions such as EGFR-induced phosphorylation of PLCγ1. This interaction takes place through the PH domain of PDK1. The loss of phosphorylation blocks PLCγ1 activity and downstream the cell migration and invasion [238], and has been considered as a lead compound for an anti-metastatic drug.

9.6 Future Directions

9.6.1 Hierarchy of Isozymes

It is unclear how the different isoforms of PLC are activated in cells receiving multiple stimuli from different receptors. With thirteen identified isoforms, expressed in multiple cell types, it will be important to define how the different signaling events that are linked to each isoform are controlled. Since PLC activation leads to release of IP_3 and DAG in response to activation, it will be important to determine how cells discriminates between multiple PLC signals to determine the hierarchy, intensity and duration of signaling events. As mentioned, PLCβ2 and PLCγ2 are activated by Rac while PLCε is activated by RhoA. These observations suggest that key regulators of cell motility function through different PLC family members, and may have pivotal roles in defining where and when a cell migrates.

PLC enzymes are found in every cell in the body, where they play critical roles in regulating diverse cellular responses (as reviewed in [28]). As mentioned, some family members serve as scaffolds for other signaling proteins, while others can serve as GAPs or GEFs, for secondary signaling proteins. Other PLCs function to amplify the Ca^{2+}oscillations in the cell. Certain PLC family members can travel to the nucleus to control signaling there. With PLC family members playing key roles in numerous cell functions, it will be important to define how each PLC is regulated and how the cellular environment affects the duration and intensity of the response.

References

1. Hokin MR, Hokin LE (1953) Enzyme secretion and the incorporation of P32 into phospholipides of pancreas slices. J Biol Chem 203(2):967–977
2. Michell RH, Allan D (1975) Inositol cyclis phosphate as a product of phosphatidylinositol breakdown by phospholipase C (Bacillus cereus). FEBS Lett 53(3):302–304
3. Takenawa T, Nagai Y (1982) Effect of unsaturated fatty acids and Ca^{2+} on phosphatidylinositol synthesis and breakdown. J Biochem 91(3):793–799
4. Streb H et al (1983) Release of Ca^{2+} from a nonmitochondrial intracellular store in pancreatic acinar cells by inositol-1,4,5-trisphosphate. Nature 306(5938):67–69
5. Suh PG et al (1988) Inositol phospholipid-specific phospholipase C: complete cDNA and protein sequences and sequence homology to tyrosine kinase-related oncogene products. Proc Natl Acad Sci U S A 85(15):5419–5423
6. Suh PG et al (1988) Cloning and sequence of multiple forms of phospholipase C. Cell 54(2):161–169
7. Kelley GG et al (2001) Phospholipase C(epsilon): a novel Ras effector. EMBO J 20(4):743–754
8. Hwang JI et al (2005) Molecular cloning and characterization of a novel phospholipase C, PLC-eta. Biochem J 389(Pt 1):181–186
9. Nakahara M et al (2005) A novel phospholipase C, PLC(eta)2, is a neuron-specific isozyme. J Biol Chem 280(32):29128–29134
10. Saunders CM et al (2002) PLC zeta: a sperm-specific trigger of Ca^{2+} oscillations in eggs and embryo development. Development 129(15):3533–3544

11. Albuquerque EX, Thesleff S (1967) Influence of phospholipase C on some electrical properties of the skeletal muscle membrane. J Physiol 190(1):123–137
12. Macchia V, Pastan I (1967) Action of phospholipase C on the thyroid. Abolition of the response to thyroid-stimulating hormone. J Biol Chem 242(8):1864–1869
13. Portela A et al (1966) Membrane response to phospholipase C and acetylcholine in cesium and potassium Ringer. Acta Physiol Lat Am 16(4):380–386
14. Trifaro JM et al (2002) Pathways that control cortical F-actin dynamics during secretion. Neurochem Res 27(11):1371–1385
15. Fukami K et al (2010) Phospholipase C is a key enzyme regulating intracellular calcium and modulating the phosphoinositide balance. Prog Lipid Res 49(4):429–437
16. Kadamur G, Ross EM (2013) Mammalian phospholipase C. Annu Rev Physiol 75:127–154
17. Sun MK, Alkon DL (2010) Pharmacology of protein kinase C activators: cognition-enhancing and antidementic therapeutics. Pharmacol Ther 127(1):66–77
18. Rosse C et al (2010) PKC and the control of localized signal dynamics. Nat Rev Mol Cell Biol 11(2):103–112
19. Akutagawa A et al (2006) Disruption of phospholipase Cdelta4 gene modulates the liver regeneration in cooperation with nuclear protein kinase C. J Biochem 140(5):619–625
20. Hashimoto A et al (2000) Cutting edge: essential role of phospholipase C-gamma 2 in B cell development and function. J Immunol 165(4):1738–1742
21. Hong J et al (2010) Bile acid reflux contributes to development of esophageal adenocarcinoma via activation of phosphatidylinositol-specific phospholipase Cgamma2 and NADPH oxidase NOX5-S. Cancer Res 70(3):1247–1255
22. Li M et al (2009) Phospholipase Cepsilon promotes intestinal tumorigenesis of Apc(Min/+) mice through augmentation of inflammation and angiogenesis. Carcinogenesis 30(8):1424–1432
23. Sun C et al (2009) Inhibition of phosphatidylcholine-specific phospholipase C prevents bone marrow stromal cell senescence in vitro. J Cell Biochem 108(2):519–528
24. Varela D et al (2007) Activation of H2O2-induced VSOR Cl^- currents in HTC cells require phospholipase Cgamma1 phosphorylation and Ca^{2+} mobilisation. Cell Physiol Biochem 20(6):773–780
25. Wahl MI et al (1989) Platelet-derived growth factor induces rapid and sustained tyrosine phosphorylation of phospholipase C-gamma in quiescent BALB/c 3T3 cells. Mol Cell Biol 9(7):2934–2943
26. Wang D et al (2000) Phospholipase Cgamma2 is essential in the functions of B cell and several Fc receptors. Immunity 13(1):25–35
27. Bunney TD, Katan M (2011) PLC regulation: emerging pictures for molecular mechanisms. Trends Biochem Sci 36(2):88–96
28. Suh PG et al (2008) Multiple roles of phosphoinositide-specific phospholipase C isozymes. BMB Rep 41(6):415–434
29. Rupwate SD, Rajasekharan R (2012) Plant phosphoinositide-specific phospholipase C: an insight. Plant Signal Behav 7(10):1281–1283
30. Harlan JE et al (1994) Pleckstrin homology domains bind to phosphatidylinositol-4,5-bisphosphate. Nature 371(6493):168–170
31. Ni T et al (2017) Structure and lipid-binding properties of the kindlin-3 pleckstrin homology domain. Biochem J 474(4):539–556
32. Kang JK et al (2017) Increased intracellular Ca^{2+} concentrations prevent membrane localization of PH domains through the formation of Ca^{2+}-phosphoinositides. Proc Natl Acad Sci U S A 114(45):11926–11931
33. Bilkova E et al (2017) Calcium directly regulates phosphatidylinositol 4,5-bisphosphate headgroup conformation and recognition. J Am Chem Soc 139(11):4019–4024
34. Jezyk MR et al (2006) Crystal structure of Rac1 bound to its effector phospholipase C-beta2. Nat Struct Mol Biol 13(12):1135–1140

35. Wen W, Yan J, Zhang M (2006) Structural characterization of the split pleckstrin homology domain in phospholipase C-gamma1 and its interaction with TRPC3. J Biol Chem 281(17):12060–12068
36. Touhara K et al (1994) Binding of G protein beta gamma-subunits to pleckstrin homology domains. J Biol Chem 269(14):10217–10220
37. Wang T et al (1999) Differential association of the pleckstrin homology domains of phospholipases C-beta 1, C-beta 2, and C-delta 1 with lipid bilayers and the beta gamma subunits of heterotrimeric G proteins. Biochemistry 38(5):1517–1524
38. Strazza M et al (2017) PLCepsilon1 regulates SDF-1alpha-induced lymphocyte adhesion and migration to sites of inflammation. Proc Natl Acad Sci U S A 114(10):2693–2698
39. Raaijmakers JH, Bos JL (2009) Specificity in Ras and Rap signaling. J Biol Chem 284(17):10995–10999
40. Kawasaki H, Kretsinger RH (1994) Calcium-binding proteins. 1: EF-hands. Protein Profile 1(4):343–517
41. Essen LO et al (1996) Crystal structure of a mammalian phosphoinositide-specific phospholipase C delta. Nature 380(6575):595–602
42. Rhee SG, Choi KD (1992) Regulation of inositol phospholipid-specific phospholipase C isozymes. J Biol Chem 267(18):12393–12396
43. Essen LO et al (1997) A ternary metal binding site in the C2 domain of phosphoinositide-specific phospholipase C-delta1. Biochemistry 36(10):2753–2762
44. Otterhag L, Sommarin M, Pical C (2001) N-terminal EF-hand-like domain is required for phosphoinositide-specific phospholipase C activity in Arabidopsis thaliana. FEBS Lett 497(2-3):165–170
45. Nomikos M et al (2015) Essential role of the EF-hand domain in targeting sperm phospholipase Czeta to membrane phosphatidylinositol 4,5-bisphosphate (PIP2). J Biol Chem 290(49):29519–29530
46. Theodoridou M et al (2013) Chimeras of sperm PLCzeta reveal disparate protein domain functions in the generation of intracellular Ca^{2+} oscillations in mammalian eggs at fertilization. Mol Hum Reprod 19(12):852–864
47. Ellis MV, S. U, Katan M (1995) Mutations within a highly conserved sequence present in the X region of phosphoinositide-specific phospholipase C-delta 1. Biochem J 307(Pt 1):69–75
48. Nagano N, Orengo CA, Thornton JM (2002) One fold with many functions: the evolutionary relationships between TIM barrel families based on their sequences, structures and functions. J Mol Biol 321(5):741–765
49. Williams RL (1999) Mammalian phosphoinositide-specific phospholipase C. Biochim Biophys Acta 1441(2-3):255–267
50. Ryu SH et al (1987) Bovine brain cytosol contains three immunologically distinct forms of inositolphospholipid-specific phospholipase C. Proc Natl Acad Sci U S A 84(19):6649–6653
51. Margolis B et al (1990) Effect of phospholipase C-gamma overexpression on PDGF-induced second messengers and mitogenesis. Science 248(4955):607–610
52. Meisenhelder J et al (1989) Phospholipase C-gamma is a substrate for the PDGF and EGF receptor protein-tyrosine kinases in vivo and in vitro. Cell 57(7):1109–1122
53. Wahl MI, Daniel TO, Carpenter G (1988) Antiphosphotyrosine recovery of phospholipase C activity after EGF treatment of A-431 cells. Science 241(4868):968–970
54. Ronnstrand L et al (1992) Identification of two C-terminal autophosphorylation sites in the PDGF beta-receptor: involvement in the interaction with phospholipase C-gamma. EMBO J 11(11):3911–3919
55. Kim HK et al (1991) PDGF stimulation of inositol phospholipid hydrolysis requires PLC-gamma 1 phosphorylation on tyrosine residues 783 and 1254. Cell 65(3):435–441
56. Gout I et al (1993) The GTPase dynamin binds to and is activated by a subset of SH3 domains. Cell 75(1):25–36
57. Bar-Sagi D et al (1993) SH3 domains direct cellular localization of signaling molecules. Cell 74(1):83–91

58. van Huizen R et al (1998) Two distantly positioned PDZ domains mediate multivalent INAD-phospholipase C interactions essential for G protein-coupled signaling. EMBO J 17(8):2285–2297
59. Yamaguchi T et al (1993) Two functionally different domains of rabphilin-3A, Rab3A p25/smg p25A-binding and phospholipid- and Ca^{2+}-binding domains. J Biol Chem 268(36):27164–27170
60. Luo JH, Weinstein IB (1993) Calcium-dependent activation of protein kinase C. The role of the C2 domain in divalent cation selectivity. J Biol Chem 268(31):23580–23584
61. Davletov BA, Sudhof TC (1993) A single C2 domain from synaptotagmin I is sufficient for high affinity Ca^{2+}/phospholipid binding. J Biol Chem 268(35):26386–26390
62. Kawasaki H, Nakayama S, Kretsinger RH (1998) Classification and evolution of EF-hand proteins. Biometals 11(4):277–295
63. Kim Y et al (2001) Chimeric HTH motifs based on EF-hands. J Biol Inorg Chem 6(2):173–181
64. Lomasney JW et al (1999) Activation of phospholipase C delta1 through C2 domain by a Ca^{2+}-enzyme-phosphatidylserine ternary complex. J Biol Chem 274(31):21995–22001
65. Montaville P et al (2007) The C2A-C2B linker defines the high affinity Ca^{2+} binding mode of rabphilin-3A. J Biol Chem 282(7):5015–5025
66. Busch E et al (2000) Calcium affinity, cooperativity, and domain interactions of extracellular EF-hands present in BM-40. J Biol Chem 275(33):25508–25515
67. Gifford JL, Walsh MP, Vogel HJ (2007) Structures and metal-ion-binding properties of the Ca^{2+}-binding helix-loop-helix EF-hand motifs. Biochem J 405(2):199–221
68. Linse S et al (1988) The role of protein surface charges in ion binding. Nature 335(6191):651–652
69. Fanning AS, Anderson JM (1996) Protein-protein interactions: PDZ domain networks. Curr Biol 6(11):1385–1388
70. Wang CK et al (2010) Extensions of PDZ domains as important structural and functional elements. Protein Cell 1(8):737–751
71. Kim JK et al (2011) Subtype-specific roles of phospholipase C-beta via differential interactions with PDZ domain proteins. Adv Enzym Regul 51(1):138–151
72. Paris L et al (2017) Phosphatidylcholine-specific phospholipase C inhibition reduces HER2-overexpression, cell proliferation and in vivo tumor growth in a highly tumorigenic ovarian cancer model. Oncotarget 8(33):55022–55038
73. Charnock-Jones DS, Day K, Smith SK (1996) Cloning, expression and genomic organization of human placental protein disulfide isomerase (previously identified as phospholipase C alpha). Int J Biochem Cell Biol 28(1):81–89
74. Bates RC et al (2014) Activation of Src and release of intracellular calcium by phosphatidic acid during Xenopus laevis fertilization. Dev Biol 386(1):165–180
75. Yelumalai S et al (2015) Total levels, localization patterns, and proportions of sperm exhibiting phospholipase C zeta are significantly correlated with fertilization rates after intracytoplasmic sperm injection. Fertil Steril 104(3):561–8.e4
76. Lagercrantz J et al (1995) Genomic organization and complete cDNA sequence of the human phosphoinositide-specific phospholipase C beta 3 gene (PLCB3). Genomics 26(3):467–472
77. Mao GF, Kunapuli SP, Koneti Rao A (2000) Evidence for two alternatively spliced forms of phospholipase C-beta2 in haematopoietic cells. Br J Haematol 110(2):402–408
78. Kim MJ et al (1998) A cytosolic, galphaq- and betagamma-insensitive splice variant of phospholipase C-beta4. J Biol Chem 273(6):3618–3624
79. Xiao W, Kawakami Y, Kawakami T (2013) Immune regulation by phospholipase C-beta isoforms. Immunol Res 56(1):9–19
80. Kawakami T, Xiao W (2013) Phospholipase C-beta in immune cells. Adv Biol Regul 53(3):249–257
81. Berstein G et al (1992) Phospholipase C-beta 1 is a GTPase-activating protein for Gq/11, its physiologic regulator. Cell 70(3):411–418

82. Runnels LW, Scarlata SF (1999) Determination of the affinities between heterotrimeric G protein subunits and their phospholipase C-beta effectors. Biochemistry 38(5):1488–1496
83. Hwang JI et al (2000) Regulation of phospholipase C-beta 3 activity by Na^{+}/H^{+} exchanger regulatory factor 2. J Biol Chem 275(22):16632–16637
84. Camps M et al (1992) Isozyme-selective stimulation of phospholipase C-beta 2 by G protein beta gamma-subunits. Nature 360(6405):684–686
85. Lee SB et al (1993) Activation of phospholipase C-beta 2 mutants by G protein alpha q and beta gamma subunits. J Biol Chem 268(34):25952–25957
86. Wang T et al (1999) Selective interaction of the C2 domains of phospholipase C-beta1 and -beta2 with activated Galphaq subunits: an alternative function for C2-signaling modules. Proc Natl Acad Sci U S A 96(14):7843–7846
87. Scarlata S et al (2016) Phospholipase Cbeta connects G protein signaling with RNA interference. Adv Biol Regul 61:51–57
88. Martelli AM et al (1992) Nuclear localization and signalling activity of phosphoinositidase C beta in Swiss 3T3 cells. Nature 358(6383):242–245
89. Kim CG, Park D, Rhee SG (1996) The role of carboxyl-terminal basic amino acids in Gqalpha-dependent activation, particulate association, and nuclear localization of phospholipase C-beta1. J Biol Chem 271(35):21187–21192
90. Payrastre B et al (1992) A differential location of phosphoinositide kinases, diacylglycerol kinase, and phospholipase C in the nuclear matrix. J Biol Chem 267(8):5078–5084
91. Ratti S et al (2017) Nuclear inositide signaling via phospholipase C. J Cell Biochem 118(8):1969–1978
92. Poli A et al (2016) Nuclear phosphatidylinositol signaling: focus on phosphatidylinositol phosphate kinases and phospholipases C. J Cell Physiol 231(8):1645–1655
93. Piazzi M et al (2015) PI-PLCbeta1b affects Akt activation, cyclin E expression, and caspase cleavage, promoting cell survival in pro-B-lymphoblastic cells exposed to oxidative stress. FASEB J 29(4):1383–1394
94. Navaratnarajah P, Gershenson A, Ross EM (2017) The binding of activated Galphaq to phospholipase C-beta exhibits anomalous affinity. J Biol Chem 292(40):16787–16801
95. Wang HL (1997) Basic amino acids at the C-terminus of the third intracellular loop are required for the activation of phospholipase C by cholecystokinin-B receptors. J Neurochem 68(4):1728–1735
96. Adamski FM, Timms KM, Shieh BH (1999) A unique isoform of phospholipase Cbeta4 highly expressed in the cerebellum and eye. Biochim Biophys Acta 1444(1):55–60
97. Min DS et al (1993) Purification of a novel phospholipase C isozyme from bovine cerebellum. J Biol Chem 268(16):12207–12212
98. Alvarez RA et al (1995) cDNA sequence and gene locus of the human retinal phosphoinositide-specific phospholipase-C beta 4 (PLCB4). Genomics 29(1):53–61
99. Park D et al (1992) Cloning, sequencing, expression, and Gq-independent activation of phospholipase C-beta 2. J Biol Chem 267(23):16048–16055
100. Harden TK, Hicks SN, Sondek J (2009) Phospholipase C isozymes as effectors of Ras superfamily GTPases. J Lipid Res 50(Suppl):S243–S248
101. Snyder JT et al (2003) The pleckstrin homology domain of phospholipase C-beta2 as an effector site for Rac. J Biol Chem 278(23):21099–21104
102. Jhon DY et al (1993) Cloning, sequencing, purification, and Gq-dependent activation of phospholipase C-beta 3. J Biol Chem 268(9):6654–6661
103. Fukaya M et al (2008) Predominant expression of phospholipase Cbeta1 in telencephalic principal neurons and cerebellar interneurons, and its close association with related signaling molecules in somatodendritic neuronal elements. Eur J Neurosci 28(9):1744–1759
104. Watanabe M et al (1998) Patterns of expression for the mRNA corresponding to the four isoforms of phospholipase Cbeta in mouse brain. Eur J Neurosci 10(6):2016–2025
105. Yang YR et al (2016) Primary phospholipase C and brain disorders. Adv Biol Regul 61:80–85
106. Koh HY (2013) Phospholipase C-beta1 and schizophrenia-related behaviors. Adv Biol Regul 53(3):242–248

107. Schoonjans AS et al (2016) PLCB1 epileptic encephalopathies; Review and expansion of the phenotypic spectrum. Eur J Paediatr Neurol 20(3):474–479
108. Kim D et al (1997) Phospholipase C isozymes selectively couple to specific neurotransmitter receptors. Nature 389(6648):290–293
109. Cocco L et al (2016) Modulation of nuclear PI-PLCbeta1 during cell differentiation. Adv Biol Regul 60:1–5
110. Ramazzotti G et al (2017) PLC-beta1 and cell differentiation: An insight into myogenesis and osteogenesis. Adv Biol Regul 63:1–5
111. Brugnoli F et al (2017) Up-modulation of PLC-beta2 reduces the number and malignancy of triple-negative breast tumor cells with a CD133(+)/EpCAM(+) phenotype: a promising target for preventing progression of TNBC. BMC Cancer 17(1):617
112. Lu G et al (2016) Phospholipase C Beta 1: a candidate signature gene for proneural subtype high-grade glioma. Mol Neurobiol 53(9):6511–6525
113. Driscoll PC (2015) Exposed: the many and varied roles of phospholipase C gamma SH2 domains. J Mol Biol 427(17):2731–2733
114. Jang HJ et al (2013) Phospholipase C-gamma1 involved in brain disorders. Adv Biol Regul 53(1):51–62
115. Epple H et al (2008) Phospholipase Cgamma2 modulates integrin signaling in the osteoclast by affecting the localization and activation of Src kinase. Mol Cell Biol 28(11):3610–3622
116. Choi JH et al (2007) Phospholipase C-gamma1 potentiates integrin-dependent cell spreading and migration through Pyk2/paxillin activation. Cell Signal 19(8):1784–1796
117. Bunney TD et al (2012) Structural and functional integration of the PLCgamma interaction domains critical for regulatory mechanisms and signaling deregulation. Structure 20(12):2062–2075
118. Arkinstall S, Payton M, Maundrell K (1995) Activation of phospholipase C gamma in Schizosaccharomyces pombe by coexpression of receptor or nonreceptor tyrosine kinases. Mol Cell Biol 15(3):1431–1438
119. Phillippe M et al (2009) Role of nonreceptor protein tyrosine kinases during phospholipase C-gamma 1-related uterine contractions in the rat. Reprod Sci 16(3):265–273
120. Buitrago C, Gonzalez Pardo V, de Boland AR (2002) Nongenomic action of 1 alpha,25(OH)(2)-vitamin D3. Activation of muscle cell PLC gamma through the tyrosine kinase c-Src and PtdIns 3-kinase. Eur J Biochem 269(10):2506–2515
121. Kusuyama J et al (2018) Spleen tyrosine kinase influences the early stages of multilineage differentiation of bone marrow stromal cell lines by regulating phospholipase C gamma activities. J Cell Physiol 233(3):2549–2559
122. Rivas M, Santisteban P (2003) TSH-activated signaling pathways in thyroid tumorigenesis. Mol Cell Endocrinol 213(1):31–45
123. Kroczek C et al (2010) Swiprosin-1/EFhd2 controls B cell receptor signaling through the assembly of the B cell receptor, Syk, and phospholipase C gamma2 in membrane rafts. J Immunol 184(7):3665–3676
124. Sato K et al (2003) Reconstitution of Src-dependent phospholipase Cgamma phosphorylation and transient calcium release by using membrane rafts and cell-free extracts from Xenopus eggs. J Biol Chem 278(40):38413–38420
125. Kim MJ et al (2000) Direct interaction of SOS1 Ras exchange protein with the SH3 domain of phospholipase C-gamma1. Biochemistry 39(29):8674–8682
126. Braiman A et al (2006) Recruitment and activation of PLCgamma1 in T cells: a new insight into old domains. EMBO J 25(4):774–784
127. Barbosa CM et al (2014) PLCgamma2 and PKC are important to myeloid lineage commitment triggered by M-SCF and G-CSF. J Cell Biochem 115(1):42–51
128. Wen R et al (2002) Phospholipase C gamma 2 is essential for specific functions of Fc epsilon R and Fc gamma R. J Immunol 169(12):6743–6752
129. Todt JC, Hu B, Curtis JL (2004) The receptor tyrosine kinase MerTK activates phospholipase C gamma2 during recognition of apoptotic thymocytes by murine macrophages. J Leukoc Biol 75(4):705–713

130. Ting AT et al (1992) Fc gamma receptor activation induces the tyrosine phosphorylation of both phospholipase C (PLC)-gamma 1 and PLC-gamma 2 in natural killer cells. J Exp Med 176(6):1751–1755
131. Hiller G, Sundler R (2002) Regulation of phospholipase C-gamma 2 via phosphatidylinositol 3-kinase in macrophages. Cell Signal 14(2):169–173
132. Kagan JC, Medzhitov R (2006) Phosphoinositide-mediated adaptor recruitment controls Toll-like receptor signaling. Cell 125(5):943–955
133. Finco TS et al (1998) LAT is required for TCR-mediated activation of PLCgamma1 and the Ras pathway. Immunity 9(5):617–626
134. Stoica B et al (1998) The amino-terminal Src homology 2 domain of phospholipase C gamma 1 is essential for TCR-induced tyrosine phosphorylation of phospholipase C gamma 1. J Immunol 160(3):1059–1066
135. Zhang W et al (2000) Association of Grb2, Gads, and phospholipase C-gamma 1 with phosphorylated LAT tyrosine residues. Effect of LAT tyrosine mutations on T cell angigen receptor-mediated signaling. J Biol Chem 275(30):23355–23361
136. Dower NA et al (2000) RasGRP is essential for mouse thymocyte differentiation and TCR signaling. Nat Immunol 1(4):317–321
137. Ebinu JO et al (2000) RasGRP links T-cell receptor signaling to Ras. Blood 95(10):3199–3203
138. Shannon LA et al (2010) CCR7/CCL21 migration on fibronectin is mediated by phospholipase Cgamma1 and ERK1/2 in primary T lymphocytes. J Biol Chem 285(50):38781–38787
139. Ji QS et al (1997) Essential role of the tyrosine kinase substrate phospholipase C-gamma1 in mammalian growth and development. Proc Natl Acad Sci U S A 94(7):2999–3003
140. Wonerow P et al (2003) A critical role for phospholipase Cgamma2 in alphaIIbbeta3-mediated platelet spreading. J Biol Chem 278(39):37520–37529
141. Inoue O et al (2003) Integrin alpha2beta1 mediates outside-in regulation of platelet spreading on collagen through activation of Src kinases and PLCgamma2. J Cell Biol 160(5):769–780
142. Garcia-Diaz Barriga G et al (2017) 7,8-dihydroxyflavone ameliorates cognitive and motor deficits in a Huntington's disease mouse model through specific activation of the PLCgamma1 pathway. Hum Mol Genet 26(16):3144–3160
143. Sims R et al (2017) Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. Nat Genet 49(9):1373–1384
144. Jiang D et al (2017) Phospholipase Cgamma1 mediates intima formation through Akt-Notch1 signaling independent of the phospholipase activity. J Am Heart Assoc 6(7)
145. Zhu L et al (2016) PLC-gamma1 is involved in the inflammatory response induced by influenza A virus H1N1 infection. Virology 496:131–137
146. Jang HJ et al (2018) PLCgamma1: potential arbitrator of cancer progression. Adv Biol Regul 67:179–189
147. Cai S et al (2017) Expression of phospholipase C isozymes in human breast cancer and their clinical significance. Oncol Rep 37(3):1707–1715
148. Woyach JA et al (2014) Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib. N Engl J Med 370(24):2286–2294
149. Koss H et al (2014) Dysfunction of phospholipase Cgamma in immune disorders and cancer. Trends Biochem Sci 39(12):603–611
150. Meldrum E et al (1991) A second gene product of the inositol-phospholipid-specific phospholipase C delta subclass. Eur J Biochem 196(1):159–165
151. Allen V et al (1997) Regulation of inositol lipid-specific phospholipase cdelta by changes in Ca^{2+} ion concentrations. Biochem J 327(Pt 2):545–552
152. Kim YH et al (1999) Phospholipase C-delta1 is activated by capacitative calcium entry that follows phospholipase C-beta activation upon bradykinin stimulation. J Biol Chem 274(37):26127–26134
153. Yamaga M et al (1999) Phospholipase C-delta1 contains a functional nuclear export signal sequence. J Biol Chem 274(40):28537–28541

154. Kunrath-Lima M et al (2018) Phospholipase C delta 4 (PLCdelta4) is a nuclear protein involved in cell proliferation and senescence in mesenchymal stromal stem cells. Cell Signal 49:59–67
155. Stallings JD et al (2005) Nuclear translocation of phospholipase C-delta1 is linked to the cell cycle and nuclear phosphatidylinositol 4,5-bisphosphate. J Biol Chem 280(23):22060–22069
156. Yoko-o T et al (1993) The putative phosphoinositide-specific phospholipase C gene, PLC1, of the yeast Saccharomyces cerevisiae is important for cell growth. Proc Natl Acad Sci U S A 90(5):1804–1808
157. Murthy KS et al (2004) Activation of PLC-delta1 by Gi/o-coupled receptor agonists. Am J Phys Cell Phys 287(6):C1679–C1687
158. Kanemaru K et al (2017) Phospholipase Cdelta1 regulates p38 MAPK activity and skin barrier integrity. Cell Death Differ 24(6):1079–1090
159. Sakurai K et al (2011) Phospholipase Cdelta3 is a novel binding partner of myosin VI and functions as anchoring of myosin VI on plasma membrane. Adv Enzym Regul 51(1):171–181
160. Kouchi Z et al (2011) Phospholipase Cdelta3 regulates RhoA/Rho kinase signaling and neurite outgrowth. J Biol Chem 286(10):8459–8471
161. Nakamura Y et al (2005) Phospholipase C-delta1 and -delta3 are essential in the trophoblast for placental development. Mol Cell Biol 25(24):10979–10988
162. Shimohama S et al (1991) Aberrant accumulation of phospholipase C-delta in Alzheimer brains. Am J Pathol 139(4):737–742
163. Yagisawa H, Tanase H, Nojima H (1991) Phospholipase C-delta gene of the spontaneously hypertensive rat harbors point mutations causing amino acid substitutions in a catalytic domain. J Hypertens 9(11):997–1004
164. Vachel L et al (2015) The low PLC-delta1 expression in cystic fibrosis bronchial epithelial cells induces upregulation of TRPV6 channel activity. Cell Calcium 57(1):38–48
165. Nakamura Y et al (2008) Phospholipase C-delta1 is an essential molecule downstream of Foxn1, the gene responsible for the nude mutation, in normal hair development. FASEB J 22(3):841–849
166. Ichinohe M et al (2007) Lack of phospholipase C-delta1 induces skin inflammation. Biochem Biophys Res Commun 356(4):912–918
167. Fukami K et al (2003) Phospholipase Cdelta4 is required for Ca^{2+} mobilization essential for acrosome reaction in sperm. J Cell Biol 161(1):79–88
168. Fukami K et al (2001) Requirement of phospholipase Cdelta4 for the zona pellucida-induced acrosome reaction. Science 292(5518):920–923
169. Shao Q et al (2017) Phospholipase Cdelta1 suppresses cell migration and invasion of breast cancer cells by modulating KIF3A-mediated ERK1/2/beta- catenin/MMP7 signalling. Oncotarget 8(17):29056–29066
170. Satow R et al (2014) Phospholipase Cdelta1 induces E-cadherin expression and suppresses malignancy in colorectal cancer cells. Proc Natl Acad Sci U S A 111(37):13505–13510
171. Shimozawa M et al (2017) Phospholipase C delta1 negatively regulates autophagy in colorectal cancer cells. Biochem Biophys Res Commun 488(4):578–583
172. Shibatohge M et al (1998) Identification of PLC210, a Caenorhabditis elegans phospholipase C, as a putative effector of Ras. J Biol Chem 273(11):6218–6222
173. Sorli SC et al (2005) Signaling properties and expression in normal and tumor tissues of two phospholipase C epsilon splice variants. Oncogene 24(1):90–100
174. Lopez I et al (2001) A novel bifunctional phospholipase c that is regulated by Galpha 12 and stimulates the Ras/mitogen-activated protein kinase pathway. J Biol Chem 276(4):2758–2765
175. Song C et al (2001) Regulation of a novel human phospholipase C, PLCepsilon, through membrane targeting by Ras. J Biol Chem 276(4):2752–2757
176. Wing MR et al (2003) Direct activation of phospholipase C-epsilon by Rho. J Biol Chem 278(42):41253–41258
177. Wing MR, Bourdon DM, Harden TK (2003) PLC-epsilon: a shared effector protein in Ras-, Rho-, and G alpha beta gamma-mediated signaling. Mol Interv 3(5):273–280

178. Malik S et al (2015) G protein betagamma subunits regulate cardiomyocyte hypertrophy through a perinuclear Golgi phosphatidylinositol 4-phosphate hydrolysis pathway. Mol Biol Cell 26(6):1188–1198
179. Madukwe JC et al (2018) G protein betagamma subunits directly interact with and activate phospholipase C. J Biol Chem 293(17):6387–6397
180. Schmidt M et al (2001) A new phospholipase-C calcium signaling pathway mediated by cyclic AMP and a Rap GTPase. Nat Cell Biol 3(11):1020–1024
181. Evellin S et al (2002) Stimulation of phospholipase C-epsilon by the M3 muscarinic acetylcholine receptor mediated by cyclic AMP and the GTPase Rap2B. J Biol Chem 277(19):16805–16813
182. Jin TG et al (2001) Role of the CDC25 homology domain of phospholipase Cepsilon in amplification of Rap1-dependent signaling. J Biol Chem 276(32):30301–30307
183. Xiang SY et al (2013) PLCepsilon, PKD1, and SSH1L transduce RhoA signaling to protect mitochondria from oxidative stress in the heart. Sci Signal 6(306):ra108
184. Wang H et al (2005) Phospholipase C epsilon modulates beta-adrenergic receptor-dependent cardiac contraction and inhibits cardiac hypertrophy. Circ Res 97(12):1305–1313
185. Tadano M et al (2005) Congenital semilunar valvulogenesis defect in mice deficient in phospholipase C epsilon. Mol Cell Biol 25(6):2191–2199
186. Chan JJ, Katan M (2013) PLCvarepsilon and the RASSF family in tumour suppression and other functions. Adv Biol Regul 53(3):258–279
187. Tyutyunnykova A, Telegeev G, Dubrovska A (2017) The controversial role of phospholipase C epsilon (PLCepsilon) in cancer development and progression. J Cancer 8(5):716–729
188. Zhang RY et al (2016) PLCepsilon signaling in cancer. J Cancer Res Clin Oncol 142(4):715–722
189. Popovics P et al (2014) A canonical EF-loop directs Ca^{2+} -sensitivity in phospholipase C-eta2. J Cell Biochem 115(3):557–565
190. Smrcka AV, Brown JH, Holz GG (2012) Role of phospholipase Cepsilon in physiological phosphoinositide signaling networks. Cell Signal 24(6):1333–1343
191. Yang YR et al (2013) The physiological roles of primary phospholipase C. Adv Biol Regul 53(3):232–241
192. Stewart AJ et al (2005) Identification of a novel class of mammalian phosphoinositol-specific phospholipase C enzymes. Int J Mol Med 15(1):117–121
193. Zhou Y et al (2005) Molecular cloning and characterization of PLC-eta2. Biochem J 391(Pt 3):667–676
194. Kouchi Z et al (2005) The role of EF-hand domains and C2 domain in regulation of enzymatic activity of phospholipase Czeta. J Biol Chem 280(22):21015–21021
195. Lo Vasco VR (2011) Role of Phosphoinositide-Specific Phospholipase C eta2 in Isolated and Syndromic Mental Retardation. Eur Neurol 65(5):264–269
196. Popovics P et al (2013) Phospholipase C-eta2 is required for retinoic acid-stimulated neurite growth. J Neurochem 124(5):632–644
197. Popovics P, Stewart AJ (2012) Phospholipase C-eta activity may contribute to Alzheimer's disease-associated calciumopathy. J Alzheimers Dis 30(4):737–744
198. Cox LJ et al (2002) Sperm phospholipase Czeta from humans and cynomolgus monkeys triggers Ca^{2+} oscillations, activation and development of mouse oocytes. Reproduction 124(5):611–623
199. Fujimoto S et al (2004) Mammalian phospholipase Czeta induces oocyte activation from the sperm perinuclear matrix. Dev Biol 274(2):370–383
200. Jones KT et al (2000) Different Ca^{2+}-releasing abilities of sperm extracts compared with tissue extracts and phospholipase C isoforms in sea urchin egg homogenate and mouse eggs. Biochem J 346(Pt 3):743–749
201. Kashir J et al (2017) Antigen unmasking enhances visualization efficacy of the oocyte activation factor, phospholipase C zeta, in mammalian sperm. Mol Hum Reprod 23(1):54–67

202. Kashir J, Nomikos M, Lai FA (2018) Phospholipase C zeta and calcium oscillations at fertilisation: the evidence, applications, and further questions. Adv Biol Regul 67:148–162
203. Aarabi M et al (2014) Sperm-derived WW domain-binding protein, PAWP, elicits calcium oscillations and oocyte activation in humans and mice. FASEB J 28(10):4434–4440
204. Aarabi M et al (2010) Sperm-borne protein, PAWP, initiates zygotic development in Xenopus laevis by eliciting intracellular calcium release. Mol Reprod Dev 77(3):249–256
205. Wu AT et al (2007) PAWP, a sperm-specific WW domain-binding protein, promotes meiotic resumption and pronuclear development during fertilization. J Biol Chem 282(16):12164–12175
206. Escoffier J et al (2016) Homozygous mutation of PLCZ1 leads to defective human oocyte activation and infertility that is not rescued by the WW-binding protein PAWP. Hum Mol Genet 25(5):878–891
207. Kashir J et al (2015) PLCzeta or PAWP: revisiting the putative mammalian sperm factor that triggers egg activation and embryogenesis. Mol Hum Reprod 21(5):383–388
208. Nomikos M et al (2015) Functional disparity between human PAWP and PLCzeta in the generation of Ca^{2+} oscillations for oocyte activation. Mol Hum Reprod 21(9):702–710
209. Nomikos M et al (2014) Sperm-specific post-acrosomal WW-domain binding protein (PAWP) does not cause Ca^{2+} release in mouse oocytes. Mol Hum Reprod 20(10):938–947
210. Satouh Y, Nozawa K, Ikawa M (2015) Sperm postacrosomal WW domain-binding protein is not required for mouse egg activation. Biol Reprod 93(4):94
211. Grasa P et al (2008) The pattern of localization of the putative oocyte activation factor, phospholipase Czeta, in uncapacitated, capacitated, and ionophore-treated human spermatozoa. Hum Reprod 23(11):2513–2522
212. Kashir J et al (2014) Sperm-induced Ca^{2+} release during egg activation in mammals. Biochem Biophys Res Commun 450(3):1204–1211
213. Young C et al (2009) Phospholipase C zeta undergoes dynamic changes in its pattern of localization in sperm during capacitation and the acrosome reaction. Fertil Steril 91(5 Suppl):2230–2242
214. Heytens E et al (2009) Reduced amounts and abnormal forms of phospholipase C zeta (PLCzeta) in spermatozoa from infertile men. Hum Reprod 24(10):2417–2428
215. Kashir J et al (2013) Variance in total levels of phospholipase C zeta (PLC-zeta) in human sperm may limit the applicability of quantitative immunofluorescent analysis as a diagnostic indicator of oocyte activation capability. Fertil Steril 99(1):107–117
216. Yoon SY et al (2008) Human sperm devoid of PLC, zeta 1 fail to induce Ca^{2+} release and are unable to initiate the first step of embryo development. J Clin Invest 118(11):3671–3681
217. Swann K et al (2006) PLCzeta(zeta): a sperm protein that triggers Ca^{2+} oscillations and egg activation in mammals. Semin Cell Dev Biol 17(2):264–273
218. Nomikos M et al (2005) Role of phospholipase C-zeta domains in Ca^{2+}-dependent phosphatidylinositol 4,5-bisphosphate hydrolysis and cytoplasmic Ca^{2+} oscillations. J Biol Chem 280(35):31011–31018
219. Halet G et al (2003) Ca^{2+} oscillations at fertilization in mammals. Biochem Soc Trans 31(Pt 5):907–911
220. Marangos P, FitzHarris G, Carroll J (2003) Ca^{2+} oscillations at fertilization in mammals are regulated by the formation of pronuclei. Development 130(7):1461–1472
221. Amdani SN et al (2016) Phospholipase C zeta (PLCzeta) and male infertility: Clinical update and topical developments. Adv Biol Regul 61:58–67
222. Wang C et al (2005) Binding of PLCdelta1PH-GFP to PtdIns(4,5)P2 prevents inhibition of phospholipase C-mediated hydrolysis of PtdIns(4,5)P2 by neomycin. Acta Pharmacol Sin 26(12):1485–1491
223. Klein RR et al (2011) Direct activation of human phospholipase C by its well known inhibitor u73122. J Biol Chem 286(14):12407–12416
224. Dwyer L et al (2010) Phospholipase C-independent effects of 3M3FBS in murine colon. Eur J Pharmacol 628(1-3):187–194

225. Frei E, Hofmann F, Wegener JW (2009) Phospholipase C mediated Ca^{2+} signals in murine urinary bladder smooth muscle. Eur J Pharmacol 610(1-3):106–109
226. Xu S et al (2009) Phospholipase Cgamma2 is critical for Dectin-1-mediated Ca^{2+} flux and cytokine production in dendritic cells. J Biol Chem 284(11):7038–7046
227. Shi TJ et al (2008) Phospholipase C{beta}3 in mouse and human dorsal root ganglia and spinal cord is a possible target for treatment of neuropathic pain. Proc Natl Acad Sci U S A 105(50):20004–20008
228. Ibrahim S et al (2007) The transfer of VLDL-associated phospholipids to activated platelets depends upon cytosolic phospholipase A2 activity. J Lipid Res 48(7):1533–1538
229. Sickmann T et al (2008) Unexpected suppression of neuronal G protein-activated, inwardly rectifying K^+ current by common phospholipase C inhibitor. Neurosci Lett 436(2):102–106
230. Kim DD, Ramirez MM, Duran WN (2000) Platelet-activating factor modulates microvascular dynamics through phospholipase C in the hamster cheek pouch. Microvasc Res 59(1):7–13
231. Muto Y, Nagao T, Urushidani T (1997) The putative phospholipase C inhibitor U73122 and its negative control, U73343, elicit unexpected effects on the rabbit parietal cell. J Pharmacol Exp Ther 282(3):1379–1388
232. Amtmann E (1996) The antiviral, antitumoural xanthate D609 is a competitive inhibitor of phosphatidylcholine-specific phospholipase C. Drugs Exp Clin Res 22(6):287–294
233. Powis G et al (1992) Selective inhibition of phosphatidylinositol phospholipase C by cytotoxic ether lipid analogues. Cancer Res 52(10):2835–2840
234. Suzuki H et al (2002) Effects of RHC-80267, an inhibitor of diacylglycerol lipase, on excitation of circular smooth muscle of the guinea-pig gastric antrum. J Smooth Muscle Res 38(6):153–164
235. Bae YS et al (2003) Identification of a compound that directly stimulates phospholipase C activity. Mol Pharmacol 63(5):1043–1050
236. Bassett AR et al (2013) Highly efficient targeted mutagenesis of Drosophila with the CRISPR/Cas9 system. Cell Rep 4(1):220–228
237. Friedland AE et al (2013) Heritable genome editing in C. elegans via a CRISPR-Cas9 system. Nat Methods 10(8):741–743
238. Raimondi C et al (2016) A Small Molecule Inhibitor of PDK1/PLCgamma1 Interaction Blocks Breast and Melanoma Cancer Cell Invasion. Sci Rep 6:26142